Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07655180 · ClinicalTrials.gov registry record · Phase 3
Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine
A Phase 3 study, sponsored by Invivyd.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 210
- Enrollment target
NCT07655180: Recruiting Phase 3 study, sponsored by Invivyd.
NCT07655180 is a Phase 3 study that is actively recruiting participants, run by Invivyd. The registered enrollment target is 210 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07655180, a Phase 3 study, is actively recruiting participants, sponsored by Invivyd.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 210 participants
- Enrollment target
Study Summary
The main purposes of this research study are to measure the safety (whether it causes any side effects), tolerability (if it does cause any side effects, how well your body is able to handle them), and reactions, both local at the injection site and systemic, that may occur in the body after receiving VYD2311, or a COVID-19 vaccine, or a combination of VYD2311 and a COVID-19 vaccine in healthy participants. This research study will measure the amount of serum virus neutralizing antibodies produced in the blood (antibodies that block a virus from infecting cells) and pharmacokinetics of VYD2311 compared to a COVID-19 vaccine, when each is administered alone or concurrently. Pharmacokinetics is the study of how a drug moves through the body, including how it is absorbed (taken into the body), distributed (spread throughout the body), metabolized (broken down in the body), and eliminated (removed from the body), and how the body affects the drug.
Interventions
- DRUG COVID-19 mRNA vaccine
- DRUG VYD2311
- DRUG Placebo (Normal Saline)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2026-06-08 |
| Est. Completion | 2026-08 |
| Phase | Phase 3 |
What NCT07655180 shows while recruiting
NCT07655180 is an interventional study that assigns participants to a tested intervention. The registered 210 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 3 interventions - of which COVID-19 mRNA vaccine is the first listed.
NCT07655180 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07655180 about?
NCT07655180 is a clinical study titled "Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine". The main purposes of this research study are to measure the safety (whether it causes any side effects), tolerability (if it does cause any side effects, how well your body is able to handle them), and reactions, both local at the injection site and systemic, that may occur in the body after receivi...
What is the current status of trial NCT07655180?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 210 participants. The study started on 2026-06-08. Estimated completion is 2026-08.
What interventions are being tested in trial NCT07655180?
The interventions under investigation include: COVID-19 mRNA vaccine (DRUG), VYD2311 (DRUG), Placebo (Normal Saline) (DRUG).
Who is sponsoring clinical trial NCT07655180?
This trial is sponsored by Invivyd, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07655180's enrollment target sits among peer trials
210 1338th of 2000 higher than 656 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02665923 · 210 participants
Gastric Emptying in Neonates and Infants After Formula Feeding
- NCT03322891 · 210 participants · NA
Improving Health Literacy in African-American Prostate Cancer Patients
- NCT03544489 · 210 participants · Phase 2
Effectiveness of Exercise After an ICD
- NCT04408430 · 210 participants · NA
The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI